nach oben

Erschienen in:

12.07.2017 | Invited Review

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review

verfasst von: Oscar Rodriguez Faba, Sabine D. Brookman-May, Estefania Linares, Alberto Breda, Francesca Pisano, José Daniel Subiela, Francesco Sanguedolce, Maurizio Brausi, Joan Palou

Erschienen in: World Journal of Urology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC), against a background of lack of evidence following the introduction of targeted therapy.

Methods

A literature review was performed in January 2017 using the MEDLINE/PubMed and EMBASE databases. The PRISMA guidelines were followed for conduct of the study. Two authors independently screened the 270 papers retrieved from the search, and the finally selected publications were identified by consensus between the two reviewers. A total of 55 studies were included in the present review.

Results

Globally, the indications for CN have decreased over recent years. Although current guidelines consider CN an adequate option in selected patients based on prospective studies in the cytokine era, evidence for CN in the era of targeted therapy is based on retrospective studies only.

Conclusions

The results of ongoing prospective studies are still awaited. Retrospective data suggest that young male patients with oligometastatic disease and a good performance status can be considered suitable surgical candidates who may benefit from CN.

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.1016/j.eururo.2015.01.005 CrossRefPubMed

Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, Lundstam S (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48(3):231–238. doi:10.3109/21681805.2013.864698 CrossRefPubMed

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241. doi:10.3322/caac.21149 CrossRefPubMed

Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, Powles T, Sternberg C, Bex A (2015) A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol 67(1):100–110. doi:10.1016/j.eururo.2014.04.006 CrossRefPubMed

Calvo E, Schmidinger M, Heng DY, Grunwald V, Escudier B (2016) Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev 50:109–117. doi:10.1016/j.ctrv.2016.09.002 CrossRefPubMed

Howick J, Chalmers I, Glasziou P (2011) Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). OCEBM

Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walther MM (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150(2 Pt 1):463–466CrossRefPubMed

Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA et al (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 108(4):518–523CrossRefPubMed

Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R, Treatment of Cancer Genitourinary G (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970CrossRefPubMed

10.

Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071–1076. doi:10.1097/01.ju.0000110610.61545.ae CrossRefPubMed

11.

Culp SH (2015) Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol 7(5):275–285. doi:10.1177/1756287215585501 CrossRefPubMedPubMedCentral

12.

Bex A, Ljungberg B, van Poppel H, Powles T, European Association of U (2016) The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol 70(6):901–905. doi:10.1016/j.eururo.2016.07.005 CrossRefPubMed

13.

Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD (2012) Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer 10(3):159–163. doi:10.1016/j.clgc.2012.03.008 CrossRefPubMedPubMedCentral

14.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi:10.1056/NEJMoa065044 CrossRefPubMed

15.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Group TS (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. doi:10.1056/NEJMoa060655 CrossRefPubMed

16.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. doi:10.1056/NEJMoa066838 CrossRefPubMed

17.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. doi:10.1016/S0140-6736(08)61039-9 CrossRefPubMed

18.

Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150. doi:10.1200/JCO.2009.26.7849 CrossRefPubMed

19.

Serie DJ, Joseph RW, Cheville JC, Ho TH, Parasramka M, Hilton T, Thompson RH, Leibovich BC, Parker AS, Eckel-Passow JE (2016) Clear cell type A and B molecular subtypes in metastatic clear cell renal cell carcinoma: tumor heterogeneity and aggressiveness. Eur Urol. doi:10.1016/j.eururo.2016.11.018 PubMed

20.

Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA (2015) Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol 33(12):528–537. doi:10.1016/j.urolonc.2015.10.003 CrossRefPubMed

21.

Li H, Samawi H, Heng DY (2015) The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol 33(12):509–516. doi:10.1016/j.urolonc.2015.08.003 CrossRefPubMed

22.

Tang PA, Vickers MM, Heng DY (2011) Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am 25(4):871–891. doi:10.1016/j.hoc.2011.04.003 CrossRefPubMed

23.

Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66(4):704–710. doi:10.1016/j.eururo.2014.05.034 CrossRefPubMed

24.

Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106(9):1266–1269. doi:10.1111/j.1464-410X.2010.09323.x CrossRefPubMed

25.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540. doi:10.1200/JCO.1999.17.8.2530 CrossRefPubMed

26.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. doi:10.1200/JCO.2008.21.4809 CrossRefPubMed

27.

Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148. doi:10.1016/S1470-2045(12)70559-4 CrossRefPubMedPubMedCentral

28.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ (2015) Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol 33(8):339, e339–e315. doi:10.1016/j.urolonc.2015.05.014 CrossRef

29.

Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S, Leppert JT (2014) Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 134(9):2245–2252. doi:10.1002/ijc.28553 CrossRefPubMedPubMedCentral

30.

Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ (2014) Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 34(5):2405–2411PubMed

31.

Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK (2014) Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int 113(5b):e67–e74. doi:10.1111/bju.12442 CrossRefPubMedPubMedCentral

32.

Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK (2016) Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study. J Clin Oncol 34(27):3267–3275. doi:10.1200/JCO.2016.66.7931 CrossRefPubMedPubMedCentral

33.

Bamias A, Tzannis K, Papatsoris A, Oudard S, Beuselinck B, Escudier B, Liontos M, Elaidi TR, Chrisofos M, Stravodimos K, Anastasiou I, Mitropoulos D, Deliveliotis C, Constantinides C, Dimopoulos MA, Bamia C (2014) Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. Clin Genitourin Cancer 12(5):373–383. doi:10.1016/j.clgc.2014.03.012 CrossRefPubMed

34.

Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185(1):60–66. doi:10.1016/j.juro.2010.09.012 CrossRefPubMed

35.

de Groot S, Redekop WK, Sleijfer S, Oosterwijk E, Bex A, Kiemeney LA, Uyl-de Groot CA (2016) Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry. Urology 95:121–127. doi:10.1016/j.urology.2016.04.042 CrossRefPubMed

36.

Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, Ost P, Devisschere P, Villeirs G, Fonteyne V, Decaestecker K (2017) The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: prognostic features in the era of targeted therapies. Urol Oncol. doi:10.1016/j.urolonc.2016.10.013 PubMed

37.

Petrelli F, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S (2016) Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer 14(6):465–472. doi:10.1016/j.clgc.2016.04.001 CrossRefPubMed

38.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. doi:10.1056/NEJMoa1510665 CrossRefPubMed

39.

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, CheckMate i (2017) CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. doi:10.1016/j.eururo.2017.02.010

40.

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659. doi:10.1056/NEJMoa003013 CrossRefPubMed

41.

AP-Hd P (2009) Clinical trial to assess the importance of nephrectomy (CARMENA) 2009. https://clinicaltrials.gov/ct2/show/record/NCT00930033?term=carmena&rank=1

42.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026 CrossRefPubMed

43.

Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Mejean A, Nathan P, Oades G, Patard JJ, Paul J, Ravaud A, Escudier B, Renal Cross Channel G (2017) Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol 71(6):845–847. doi:10.1016/j.eururo.2016.10.029 CrossRefPubMed

44.

Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M (2013) In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol 63(6):1107–1114. doi:10.1016/j.eururo.2012.08.069 CrossRefPubMed

45.

Jackson BL, Fowler S, Williams ST, British Association of Urological Surgeons-Section of O (2015) Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012. BJU Int 116(6):905–910. doi:10.1111/bju.12890 CrossRefPubMed

46.

Silberstein JL, Adamy A, Maschino AC, Ehdaie B, Garg T, Favaretto RL, Ghoneim TP, Motzer RJ, Russo P (2012) Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). BJU Int 110(9):1276–1282. doi:10.1111/j.1464-410X.2012.11103.x CrossRefPubMedPubMedCentral

47.

Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, Leibovich BC, Thompson RH (2016) Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol 69(1):84–91. doi:10.1016/j.eururo.2015.05.022 CrossRefPubMed

48.

Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, Attwood K, Kauffman E, Spiess P, Wagner A, Schwaab T (2016) Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. World J Urol 34(12):1651–1656. doi:10.1007/s00345-016-1827-1 CrossRefPubMed

49.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM (2001) Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 166(1):68–72CrossRefPubMed

50.

Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, Shariat SF, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI (2013) Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. Ann Surg Oncol 20(6):2096–2102. doi:10.1245/s10434-012-2806-4 CrossRefPubMed

51.

Patel HD, Gorin MA, Gupta N, Kates M, Johnson MH, Pierorazio PM, Allaf ME (2016) Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. Can Urol Assoc J 10(11–12):389–395. doi:10.5489/cuaj.1999 CrossRefPubMedPubMedCentral

52.

Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169(6):2076–2083. doi:10.1097/01.ju.0000066130.27119.1c CrossRefPubMed

53.

Lughezzani G, Capitanio U, Jeldres C, Isbarn H, Shariat SF, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI (2009) Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer 115(24):5680–5687. doi:10.1002/cncr.24682 CrossRefPubMed

54.

Gershman B, Thompson RH, Moreira DM, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC (2017) Lymph node dissection is not associated with improved survival among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma: a propensity score based analysis. J Urol 197(3 Pt 1):574–579. doi:10.1016/j.juro.2016.09.074 CrossRefPubMed

55.

Feuerstein MA, Kent M, Bernstein M, Russo P (2014) Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis. Int J Urol 21(9):874–879. doi:10.1111/iju.12457 CrossRefPubMedPubMedCentral

Titel: Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review
verfasst von: Oscar Rodriguez Faba
Sabine D. Brookman-May
Estefania Linares
Alberto Breda
Francesca Pisano
José Daniel Subiela
Francesco Sanguedolce
Maurizio Brausi
Joan Palou
Publikationsdatum: 12.07.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 12/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2072-y

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2017

Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes

‘Real-life experience’: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC—a prospective controlled study

Effect of endoplasmic reticulum stress inhibition on hyperoxaluria-induced oxidative stress: influence on cellular ROS sources

Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment

The “old” 15 mm renal stone size limit for RIRS remains a clinically significant threshold size

Oncologic surveillance following radical cystectomy: an individualized risk-based approach

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie